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Abstract 
 
 T regulatory cells are part of the immune system and act to control and suppress 
immune responses. A small population or a population of T regulatory cells with impaired 
function has been associated with allergic and autoimmune diseases. Without suppression 
from these cells, immune dysfunction can become prevalent and lead to disease. Previous 
studies have shown that exposure to microbes and parasites such as Helminths can boost the 
T regulatory cell population. In developed countries, where microbial and parasitic exposure 
is diminished, allergies and autoimmune disorders are on the rise. In this review, scholarly 
articles and recent clinical trials were examined to see what therapies are currently being 
tested using T regulatory cells. One of the most favorable therapies is adoptive transfer of T 
regulatory cells. This therapy has had promising results in the early stages. Patients who 
received adoptive transfer therapy have had more alleviation of their disease than those in the 
control groups who received traditional treatment. Future studies need to be done to come to 
clear conclusions about the effectiveness of adoptive transfer, which would include a larger 
sample size of patients and longer follow up periods after therapy. By improving our 
understanding of adoptive transfer as a treatment, patients with these disorders can hopefully 
have an improved quality of life in the future.     
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Introduction 
 
 In Western countries the rates of allergic diseases, including asthma, food allergies, and 
hay fever, have been on the rise for the past several decades (Versini et al. 2015). Hay fever was 
first described in 1819 by a man named John Bostock. Bostock had symptoms for years but 
could not find a physician who could diagnosis him. Being a doctor himself, he found other 
people who had similar symptoms and were undiagnosed (Platts-Mills 2015). It wasn’t until the 
1870’s when Dr. Blackley, after using a skin test with grass pollen, concluded that hay fever was 
a reaction to pollen. Unlike hay fever, asthma had been around for years, however, it was not 
common until the 1960’s. Similarly, the rates of food allergies, specifically peanut allergy, did 
not rise until the 1990’s (Platts-Mills 2015). 
 Why have allergic diseases increased so suddenly and rapidly? In 1989, Dr. David 
Strachan noticed an inverse relation between hay fever and number of older siblings. Doctor 
Strachan suggested that this disease was prevented in younger siblings through "infection in 
early childhood, transmitted by unhygienic contact with older siblings."(Brookes and Cheng 
2015). He called this idea the “hygiene hypothesis” and it has expanded greatly since then. Now, 
the general belief is that through the increase of hygiene in developed countries, exposure to 
microbes has decreased. The decrease in exposure has led to an unregulated immune system, 
resulting in not only allergic disorders, but autoimmune diseases too. Microbes, or 
microorganisms, are things too small to see with the naked eye, such as bacteria, viruses, or a 
fungus. Factors that have led to the decrease in microbial exposure include decontamination of 
water, vaccination, widespread use of antibiotics, and lifestyles changes (Okada et al. 2010). 
 Several population studies have been done that support the hygiene hypothesis. One 
study was conducted by Dr. Mark Holbreich and colleagues. They studied the prevalence of 
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allergic diseases among Amish children, versus Swiss farm and non-farm children. The Amish 
immigrated to the United States about two hundred years ago from Switzerland (Holbreich et al. 
2012). Amish families typically live and work on farms. Their lifestyle includes no electricity, 
large families, drinking raw milk, and daily exposure to livestock. Prevalence of asthma was 
5.2%, 6.8%, and 11.3% among Amish, Swiss farm, and Swiss non-farm children. Overall 
allergic sensitization was 7.2%, 25.2%, and 44.2% respectively. Reaction to dust mite and grass 
pollen was lower among Amish children as well (Holbreich et al. 2012). This study gives insight 
that living in a pre-hygienic community, such as the Amish, provides protection against allergic 
disorders. Another study comes out of Finland. The region of Karelia is characterized by a 
Finnish section, with high standards of hygiene, and a Russian section, with lower standards of 
hygiene. Finnish Karelians have much higher rates of allergic and autoimmune disorders than 
Russian Karelians, despite sharing the same genetic background. One example is that the 
incidence of the autoimmune disorder Type 1 Diabetes (T1D) is six times higher among Finnish 
than Russian Karelians (Kondrashova et al. 2013).  
 While genetics does play a role in the development of these disorders, it is not the sole 
factor. The case above is a prime example, as the Karelian population shares similar genetic 
backgrounds with one another. Migration studies also show that descendants of immigrants who 
came from a country of low disease incidences, acquire the same incidence as the host country 
(Versini et al. 2015). This is seen in African Americans, who have a much higher rate of the 
autoimmune disorder systemic lupus erythematosus than West Africans do (Symmons 1995).  To 
understand why this is occurring, it helps to understand how the immune system responds to 
microbes.  
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Overview of the Immune System 
 The immune system of an individual has two immune responses, the innate immune 
response and the adaptive immune response. Though different, these two responses work 
together to defend the host from invading pathogens. Pathogens are disease causing microbes or 
parasites, but not all microbes cause disease. The innate immune response and the skin barrier 
are considered the first line of defense when fighting off a pathogen and are known to be 
nonspecific because it doesn’t recognize specific pathogens, but a spectrum of microbes that 
don’t belong to the host. It consists of natural barriers such as the skin, as well as white blood 
cells known as leukocytes. The main types of innate leukocytes are neutrophils, macrophages, 
eosinophils, basophils, and mast cells, each with a specific role. Eosinophils and basophils 
primarily defend against parasites. Mast cells are found in tissue such as the skin and can release 
histamine to instigate an inflammatory response (Stranford et al. 2013). Neutrophils and 
macrophages are known as phagocytes because they consume dead cell debris and microbes such 
as bacteria. This process is called phagocytosis. Macrophages can also be classified as antigen 
presenting cells (APCs) along with dendritic cells. APCs will phagocytize a pathogen and then 
present an antigen from the pathogen on their surface. Antigens are molecules that initiate an 
immune response. In the case of APCs, antigens come from a pathogen and are used to activate 
an adaptive immune response. 
 APCs take the antigen and present it to T cells of the adaptive immune response. Cells of 
the adaptive immune response are highly specific and will only recognize one antigen each. 
These cells are called lymphocytes which include B cells and T cells. APC’s will present an 
antigen to T cells. When they are presented with an antigen which they recognize, they will 
become activated. B cells have antibodies on their surface, which can recognize antigens and 
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activate the cells. When activated, B cells will produce more antibodies to that antigen. The 
antibodies can bind to the antigen, which is part of the pathogen, and neutralize it or attract other 
immune cells to kill the pathogen. T cells serve many different functions. T helper cells serve as 
a helper to the adaptive immune response. When activated by an APC, they will go and find 
other B or T cells that recognize the same antigen and activate them using chemical signals 
called cytokines. Cytotoxic T cells, once they are activated, will kill cells infected with that 
specific pathogen. They do this by inducing cell death in infected cells by a process called 
apoptosis (Stranford et al. 2013). 
 Since lymphocytes are capable of recognizing specific antigens, it is necessary that they 
only recognize foreign antigens, and not one’s own antigens, known as self-antigens. To exclude 
any self-reactive lymphocytes, they undergo a selection process. This occurs in the bone marrow 
for B cells and in the thymus for T cells. The thymus is an immune organ near the front of the 
heart that T cells get their name from. Any cells that are self-reactive are not allowed to survive 
and die by apoptosis. This is called self-tolerance, as the surviving cells will tolerate the self-
antigen and not respond to it.  
 
Mechanism of Tolerance  
 
The population studies that have supported the hygiene hypothesis have led researchers to 
wonder what is happening inside the body that promotes either tolerance or dysfunction. Studies 
have concluded that it comes down to different subsets of T cells. In one subset, T helper cells, 
researchers have been able to identify connections to allergic and autoimmune disease. Two 
specific types of T helper cells (TH) are T helper Type 1 cells (TH1) and T helper Type 2 cells 
(TH2). In autoimmune patients, TH1 is the dominant T helper cell, while in allergic patients, TH2 
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is the dominant type (Versini et al. 2015). In normal, healthy individuals, the two types are in a 
reasonable balance, but with patients that have immune dysfunction, there is an imbalance.  
There is also another subset of T cells that is critical; the T regulatory cell (Treg). The Tregs 
role in the immune response is to suppress it. The idea of Tregs was first developed in the 1970’s 
when researchers noticed that tolerance to foreign cells could be transferred among different 
mice using T cells (Gershon and Kondo 1971). Due to technology at the time however, it was 
impossible to identify the specific subset of T cells that caused tolerance. Since there was no way 
to identify these cells, the idea of transferred tolerance was not well favored. It wasn’t until many 
years later that the subset would be identified as Tregs (Kuhn et al. 2016). As stated, these cells 
induce immune suppression and prevent the immune system from becoming overactive and 
harmful to the individual. There are many types of regulatory T cells that have been discovered, 
but the main two are native T regulatory cells (nTregs) and induced T regulatory cells (iTregs) 
(Braga et al. 2012). Native T regulatory cells are selected for in the thymus and are then used to 
prevent autoimmune disorders. Normally, any self-reactive T cells would not be allowed to 
survive in the thymus, but occasionally a couple may slip through the selection process. The 
purpose of the nTregs would be to suppress the activity of these self-reactive T cells. Induced T 
regulatory cells were once TH cells that encountered a foreign antigen. In the presence of the 
signal interleukin 10 (IL-10) and transforming growth factor beta (TGF-β), a small percentage of 
TH cells will become iTregs (Braga et al. 2012). Since Tregs show the capability of suppressing the 
immune system, which is overactive in allergies and autoimmune disorders, they have become a 
central focus in research to prevent the development and alleviate the symptoms of such 
diseases.  
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Tregs get their suppression function from the transcription factor known as forkhead box 
P3 (FOXP3). FOXP3 is considered a master regulator and is what gives Tregs their regulatory 
function. This factor is used to identify Tregs, thus they are said to be FOXP3+ T cells (Ng et al. 
2013). It is worth noting however, that other forms of Tregs, lacking FOXP3, have been identified 
(Braga et al. 2012). Loss of function mutations in the FOXP3 gene have resulted in Treg 
deficiency and severe immune disorders (Ng et al. 2015). One genetic disorder is IPEX 
syndrome where there is a complete loss of function from FOXP3. Individuals with IPEX 
syndrome will demonstrate multiple organ autoimmunity (Aricha et al. 2016). Studies have 
shown that in patients with overactive immune systems, the population of Tregs is either 
diminished or does not function properly.  
 Tregs use a couple of different mechanisms to achieve immune system suppression. One of 
the most well documented ways is through the secretion of the cytokine IL-10. Cytokines are 
substances secreted by one immune cell, which can have an effect on another immune cell. It is a 
way for immune cells to communicate with each other. Most cytokines are referred to as 
interleukins, such as interleukin 10, which is considered to be an anti-inflammatory cytokine. 
Animals that had a deficiency in IL-10 or are treated with anti-IL-10 antibodies died rapidly 
when infected with parasites such as Toxoplasma gondii. Death did not occur from the parasite 
itself, but rather from overproduction of inflammatory cytokines (Gazzinelli et al. 1996). T. 
gondii is a common parasite that can infect any warm blooded animal. Infection may produce 
mild flu like symptoms, but most infections are asymptomatic. The parasite is harmless in many 
cases so death occurred because in the absence of IL-10, the immune response was not able to be 
suppressed and hyperactivation occurred.  
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 In healthy individuals, Tregs will function to suppress the immune system by suppressing 
antigen-presenting cells and TH1 and TH2 cells, using IL-10 and TGF-β. If given antibodies to 
block these cytokines, suppression is also blocked and levels of these cells will return to what 
they were prior to suppression (Braga et al. 2012). Similarly, Tregs can also suppress mast cells, 
basophils, and eosinophils. Tregs also perform regulatory functions on B cells. Secretion of IL-10 
can downregulate the production of IgE and enhance the production of IgG4 and IgA (Braga et 
al. 2012). Ig stands for immunoglobulin, also known as an antibody. There are five classes of 
antibodies shown in the table below. 
 
Table 1: Antibody Classes (Rahman 2016) 
Antibody 
Name 
Role Subclasses 
IgM - Responses to first exposure of antigen  None 
IgD - Located on the surface of B cells with IgM None 
IgG - Expressed on the surface of B cells 
- Involved in secondary immune response 
4  
IgE - Triggers histamine release 
- Protects against parasitic worms 
None  
IgA - Found in saliva, tears, and mucus  2 
 
 There is also another type of regulatory cell known as the B regulatory cell (Breg). B cells 
secrete antibodies which fight off invading pathogens, but in allergies and autoimmune disorder, 
antibodies can cause an array of problems. In autoimmunity, these antibodies can be self-
reactive, while in allergies, IgE activates the release of histamine from mast cells, eosinophils, 
and basophils which causes an allergic reaction (Braza et al. 2014). However, similarly to Tregs, 
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Bregs exist to suppress any unwanted activity from the B cell population and they achieve this by 
the secretion of IL-10. Bregs are able to inhibit cytokine secretion from TH1 and TH2 cells, 
particularly proinflammatory cytokines. Bregs are also able to recruit or induce a population of 
FOXP3+ Tregs. Lastly, Bregs are also capable of producing apoptosis in activated T cells (Smits 
2012). Unlike Tregs, which are mainly characterized as being FOXP3+, there is no specific 
marker to identify Bregs. Therefore, they are hard to identify and understand where they originate 
from.  
 
In the Case of Helminths  
 Helminths are parasitic worms that often reside in the intestine of humans. Years ago, 
infection with Helminths was very common. Almost everybody at some point in their lifetime 
would come into contact with a worm and become infected (Maizels 2016). Today, about 37% of 
the world’s population is infected with Helminths, mainly in developed countries (Versini et al. 
2015). The decrease in infections is associated with sanitation of water, as well as access to 
antihelmintic treatments. Certain types of Helminths can be highly pathogenic, but most 
infections are often asymptomatic (Maizels 2016). 
 Helminths have a long evolutionary history and it is believed that humans co-evolved 
with them. The reason for this is that the parasite does not want to kill their host, but rather live 
inside of them. To achieve this the parasite must modulate the immune system to keep the host 
from attacking and killing it. The parasite is capable of living peacefully in the human body 
because an attack on the parasite from the immune system would be very burdensome, and the 
body is likely to become infected again shortly after. The immune system is able to overlook the 
infection and focus on more harmful pathogens (Weinersmith and Earley 2016).  The parasite is 
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also capable of upregulating TH2 while inhibiting the TH1 response. Normally, a high TH2 
response would be a characteristic of allergic disorders, however, the Helminth worm also 
upregulates a population of Tregs, which will prevent the TH2 cells from having abnormal activity 
(Versini et al. 2015). The Treg population with its immune suppressive capabilities not only 
allows the parasite to survive, but can aide in the prevention of allergic and autoimmune 
disorders in the host.  
 Since Helminths have been able to aid humans, they have been give the name “old 
friends”. The human population has lived in contact with “old friends” for millennia, up until a 
couple of decades ago (Versini et al. 2015). As society began to change, people moved away 
from farms and more hygienic ways were developed, we successfully decreased exposure to 
harmful microbes, but also decreased the exposure to “old friends”. It has been theorized that 
since we evolved for so many years with the parasites, that many of us now do not possess the 
capabilities of creating a substantial Treg population on our own (Weinersmith and Earley 2016).  
 Knowing that undeveloped countries have lower rates of allergic and autoimmune 
disorders while having higher rates of infections from parasites, has prompted numerous studies 
to look at the role infections play in the development and the treatment of these disorders. There 
have been both positive and negative results from these studies. One study out of Argentina 
followed twelve patients with the autoimmune disorder multiple sclerosis. The patients who had 
active helminth infection all went into remission for four years, while uninfected individuals had 
numerous relapses (Correale and Farez 2011). The patients in remission showed increased levels 
of IL-10, TGF-β, Bregs, and Tregs. Another study looked at inflammatory disorders of the gut such 
as Crohn's disease and ulcerative colitis. Patients were infected with the eggs from the parasite 
Trichuris suis. About 70% of the patients showed improvement in their symptoms (Summers et 
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al. 2005). While these results are promising, a problem with both studies is that the study size is 
too small to consider the results significant.  
 Other studies have had mixed results. There are a couple reasons for this. One is that 
there are many different types of Helminth species being investigated for a wide range of 
disorders. The different species and different diseases increase the variables, which makes it 
difficult to come up with uniform conclusions about whether a specific parasite can benefit a 
specific disease or not. Another reason for mixed results is that these disorders are not caused 
solely by the absence of parasites, but also by genetic and environmental factors. Infection by a 
Helminth parasite may not be able to help individuals who are genetically susceptible to a 
disorder as parasitic infection is not the cause. In patients whose disease is not well controlled, it 
is worth the investigation to see if Helminths can alleviate their symptoms.  
 Some researchers have looked at Helminths not as a treatment, but as a preventative 
measure. They have studied the effect of parasitic infections on infants and children. These 
studies have had more consistent results. One study concluded that infection by the worm 
Trichuris trichiura in early childhood is associated with reduced odds of allergic reactivity in 
adulthood (Amoah et al. 2013). During pregnancy, infection with Helminths of the mother is 
associated with lower odds of the newborn developing allergic eczema. When given 
antihelminthic treatment, children had an increased reaction to allergens (Amoah et al. 2013). 
This occurred because allergens promote B cells to produce the antibody IgE. During infection, 
the Helminth worms can upregulate Tregs, which reduce the responsiveness of the IgE. After 
treatment, with no infection, there is no Treg upregulation, and the IgE antibodies are able to 
induce an allergic reaction (Amoah et al. 2013).  
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 Altogether, worm infections early in life have a preventive effect on the development of 
allergic and autoimmune diseases. In parents with one of these diseases that may increase the 
chance of the child developing it, Helminth treatment as a possible preventive measure may be 
possible. More research needs to be done on the safety of Helminth treatment in children 
beforehand, however.  
Tregs in Immunotherapy  
 Immunotherapy is the prevention or treatment of disease with a substance that will 
stimulate an immune response. In allergies, allergen-specific immunotherapy (SIT) has been 
used for many years. With SIT, the patient is given gradually increasing doses of an allergen, 
usually through a shot in the skin, over a period of time with the hopes that the patient will 
become tolerant to that allergen. The aim of this treatment is to restore balance of the immune 
system in allergic individuals. Though SIT has been around for 100 years and has been known to 
work, the mechanism of how SIT worked was unknown for quite some time (Eiwegger et al. 
2012).  
 As researchers discovered more information about Tregs, they began to realize the 
important role these cells play in the development and alleviation of allergic diseases. In children 
who outgrow allergies to cow’s milk, they have a higher frequency of circulating Tregs in their 
blood when compared to children who continue to have the allergy (Karlsson et al. 2004). The 
Tregs suppress the inflammatory response and contribute to the generation of IgG4 antibodies, 
rather than IgE antibodies that incite an inflammatory response. The cytokine IL-10 is found to 
be a key molecule secreted from Tregs that inhibits T cell activation and ultimately restores 
balance in the immune system to a state of tolerance. Another effect of SIT is that the small 
dosage of allergen does generate some release of histamine from mast cells. This release is below 
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the threshold to cause an allergic reaction. By doing this, the contents of the cells are diminished 
and the level of allergen exposure needed to cause a reaction is increased (Eiwegger et al. 2012).  
 During SIT, the gradually increasing exposure to an antigen that the patient is allergic to 
allows for the immune system to produce IgG4. This antibody exhibits a blocking effect as it will 
bind to the antigen before IgE is able to. Thus, IgE antibodies are unable to bind and cause 
histamine release of neighboring mast cells (Eiwegger et al. 2012). The increase in IgG4 levels 
can serve as a marker for Treg cell activity, as Tregs are able to promote the production of IgG4 
instead of IgE. Overall, SIT actually increases the Treg population and increased levels of IgG4 
antibodies are a product of that. As well as restoring Treg levels, SIT can shift away from the pro-
allergic state of dominant TH2, to a more tolerant state of TH1 cells (Eiwegger et al. 2012).  
 A study on mice demonstrated the principle of acquired tolerance through the use of SIT. 
Professor Yamashita and colleagues studied allergic reaction in mice while treating them with 
SIT (Yamashita et al. 2011). Pretreating mice with a gradually increasing doses of the allergen 
prevented allergic reaction from occurring. The researchers also studied adoptive transfer in the 
mice. Here, they took Treg cells from mice that had a tolerance to the allergen and injected them 
into mice that had the allergy. After treatment, the mice did not demonstrate an allergic reaction 
to the allergen as they previously did (Yamashita et al. 2011). One aspect that was different 
however was that levels of IgE were reported to have increased in the mice, though no allergic 
symptoms were seen to be occurring in the mice. They found that the antibodies were able to 
bind to the allergen, but it was believed that the Tregs prevented the bound antibodies from 
starting a reaction (Yamashita et al. 2011).  
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Tregs in Type 1 Diabetes 
 Type 1 Diabetes (T1D) is an autoimmune disorder that affects the pancreas. Causes of 
T1D include genetic and environmental factors, as well as infection with certain viruses (Creusot 
et al. 2016). Cells in the pancreas that are affected are called beta islet cells. These cells produce 
insulin that allow other cells in the body to take up glucose, a form of sugar. In T1D, T cells are 
self-reactive and they recognize the beta islet cells, attacking them and eventually destroying 
them (ElEssawy and Li 2015). The destroyed cells can no longer produce insulin, causing the 
rest of the body’s cells to be affected where they cannot take in glucose, leading them to starve. 
To avoid this, patients take insulin shots to allow the cells to take in glucose from the blood. T1D 
affects about 1.25 million people in the United States and rates are increasing every year 
(Gitelman and Bluestone 2016). Projections suggest that the number of affected individuals will 
triple by the year 2050 (Gitelman and Bluestone 2016). Insulin replacement has improved the 
life of individuals affected but blood sugar levels are still hard to control and patients develop 
different complications over the years (Perakakis and Mantozoros 2016). Unsatisfactory 
treatment has led researchers to continually investigate not only new treatments, but preventative 
measures for high risk individuals. 
 Numerous studies have shown that Tregs play a large role in T1D. In patients with T1D, 
Treg numbers are deficient, the cells have impaired function, or other immune cells are 
unresponsive to the Tregs (ElEssawy and Li 2015). Secondly, though self-reactive T cells are the 
main effector of T1D, they are not the first to cause damage. Recent studies have shown that 
cells of the innate immune system, such as macrophages and dendritic cells, are the first to enter 
the pancreas and cause increased inflammation followed by the infiltration of the self-reactive T 
cells. It is believed that this is caused by infection from certain viruses. The viruses may kill the 
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beta islet cells, than macrophages present islet cell antigens to T cells, where self-reactive ones 
will become activated (Perakakis and Mantozoros 2016). In mice studies, non-obese mice 
showed an increase in the rates of T1D when they had a decreased population of Tregs (Perakakis 
and Mantozoros 2016). Relating back to the hygiene hypothesis, mice that were raised in a germ 
free environment were also more likely to develop T1D (Wen et al. 2008). This type of T1D was 
not actually caused by self-reactive T cells, but from cells of the innate immune system. The lack 
of microbes in the mice led to a poor development of Tregs causing the overall immune system to 
become dysregulated (Wen et al. 2008). 
  Treg cells have become the focus of potential treatment because restoration of the Treg 
population could potentially suppress the self-reactive T cells that are causing damage to the 
pancreas. They are also being studied for possible preventative measures because Tregs can 
suppress the initial inflammation caused by the innate immune cells. Preventative treatment for 
high risk individuals is very significant because by the time an individual is diagnosed with T1D, 
on average about 40% of their beta islets cells have already been destroyed (Perakakis and 
Mantozoros 2016). 
 T1D is just one example of many autoimmune disorders which seem to be following the 
same trend, that one of the major underlying problems is the Treg population. The population of 
Tregs in affected individuals is decreased and if not decreased, the Tregs have impaired function 
and are ineffective at suppressing other immune cells. Though this is not the case for every 
individual, it is a general trend that has been noticed over the years. This has led to the focus on 
Tregs as potential targets for immunotherapy.  
 
 
15 
 
Adoptive Transfer of Tregs 
 The therapy of adoptive transfer consists of taking cells and transferring them into a 
patient. The cells can come from either the patient or another individual. Since Tregs have been 
shown to be an important immune cell in allergies and autoimmune disorders, they have been 
implemented in this type of therapy. Typically, samples are taken from the patient and the 
sample undergoes a purification process to isolate T cells. These cells undergo further isolation 
so that only Tregs remain. The sample of Tregs is then cultured so that a substantial population 
exist. This is done by introduction of cytokines such as IL-10 and IL-2 which stimulate the 
production of Tregs (Trzonkowski et al. 2015). The Tregs must then be tested to make sure that 
they function properly. In the case of autoimmune disorders, the cells must also be tested to be 
sure that none of them are able to recognize and attack host cells. The original self-reactive T 
cells must not be in the new Treg population. From here, the cells are transferred back into the 
patient, either through the blood or into a site effected by the disorder, like the pancreas in T1D. 
 Testing adoptive transfer therapy was first done using mice as subjects. It has been shown 
that Tregs from a non-allergic mouse that are transferred to an allergic mouse will induce 
tolerance in the recipient mouse (Yamashita et al. 2011). Likewise, mice with T1D who undergo 
adoptive transfer therapy of Tregs have been able to either alleviate symptoms of the disease or 
stop further damage to the pancreas and restore insulin production (Gitelman and Bluestone 
2016). Tregs have also been tested in transplants, to prevent graft-versus-host disease (GVHD) 
where cells from the donated blood or bone marrow recognize the recipient cells as foreign and 
attack the recipient. Tregs have also been evaluated to see if they can prevent or improve the risk 
of rejection of the transplanted organ. Transfer of other immune cells, such as TC and TH cells are 
also being investigated to determine if these immune cells can attack cancer cells in the body.  
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 The first human studies done with adoptive transfer were done only to determine if it was 
safe to transfer Tregs into a person, not to determine if there was any alleviation of disease 
(Gitelman and Bluestone 2016). So far, transfer of Tregs has been seen to be safe with minimal 
side effects. Some studies however, have reported an increase in the rate of cancer and 
infections, but in the control group there was also increased rates of cancer and infection (Todo 
et al. 2016). Once safety was established, researchers needed to know how many Tregs need to be 
transferred into a patient to achieve suppression and what is the maximum limit of Tregs that 
should be given to the patient. In mice, large numbers of Tregs are needed to reverse T1D, around 
5x106 cells infused. However, mice are much smaller creatures than humans, therefore a much 
larger sample is needed, around 3x108 cells per dose (Tang and Lee 2012). This is just a general 
estimate, as every disease and person is unique and will require different amounts of cells to 
achieve suppression. The upper limit of how many cells that can safely be transferred is near the 
limit of the number of cells that can be produced in culture with current methods (Gitelman and 
Bluestone 2016). Once safety and numbers had been established trials went on to test the 
effectiveness of adoptive transfer in treating autoimmune and allergic disorders, as well as 
preventing GVHD and organ transplant rejections. Results of some trials are explained below, 
while many trials are still being currently conducted. 
    
Autoimmune Disorders 
Type 1 diabetes is possibly one the most popular autoimmune disorders that is being used 
in research of the effectiveness of Treg cell transfer. One group out of the University of California 
recently published results from their trials this year, 2016 (Gitelman and Bluestone 2016). They 
first established that there was no increased risk of infection among patients. They also 
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established that it is feasible to obtain blood from a patient, isolate the Tregs, allow them to grow 
in culture, and infuse them back into the patient. The Treg population that was infused in the 
patient declined over the course of nine months but a prolonged presence was seen till the end of 
the study, a year out from initial infusion. Twelve patients were used and one year after the 
study, eight of those patients achieved clinical remission, while in the control group, only two 
out of ten patients had achieved remission (Gitelman and Bluestone 2016). The patients were 
also sorted into different groups and each group was given a different dose of Tregs. Results 
suggested that a higher dose of Tregs is better as the patients that received the higher dose were 
completely off of supplemental insulin (Gitelman and Bluestone 2016). One significant problem 
with this study is that the sample size is very small, only twelve patients being studied. The small 
size prevents any results from being considered significant.  
Another study done by Dr. Marek-Trzonkowski and colleagues had similar results to the 
previous study. At the end of the study, one year after infusion, patients that received Treg 
infusion on average required half the amount of insulin injections than those in the control group, 
while two individuals did not require insulin injections at all (Trzonkowski et al. 2008). These 
patients had all received Treg infusion around two months after initial diagnosis of T1D. Transfer 
early on in diagnosis is important because throughout the course of the disease, beta islet cells 
are slowly destroyed. The longer an individual has had T1D, the more cells in the pancreas have 
been destroyed. To preserve optimal function of the pancreas, it is necessary to try treatment 
very early.  
Since large numbers of cells in the pancreas are destroyed by the time of diagnosis, 
adoptive transfer has been tested as a preventative measure for high risk individuals in order to 
prevent pancreatic damage. Individuals are deemed high risk if they have a family history of 
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T1D or they have genetic risks factors (Creusot et al. 2016). Several animal studies have shown 
that adoptive transfer of Tregs amongst animals at risk for T1D can prevent the development of 
the disease. Future trials need to be conducted to see if results from animal models will correlate 
to human subjects. One potential problem is that children are typically the patients that are 
considered to be high risk as the majority of T1D cases are diagnosed at age fourteen. The 
problem here is that adoptive transfer requires a large initial volume of blood to be taken from 
the patient, a volume that children may not be able to safely give (Gitelman and Bluestone 2016). 
A way around this would be to take a smaller amount of cells from the patient, but increase the 
growth rate of the Tregs in culture.  
Another autoimmune disorder being investigated is myasthenia gravis (MG). MG is a 
disease characterized by muscle weakness and fatigue from immune cells attacking skeletal 
muscle receptors (Aricha et al. 2016). Overtime, the communication between muscles and nerves 
is broken down. Some individuals can live normal lives with medications, while others still 
develop serious complications. Researchers at The Institute of Science in Israel looked at Tregs as 
a possible treatment for MG. They used rats as their model and induced them with experimental 
MG, which is very similar to normal MG (Aricha et al. 2016). First, they took Tregs from healthy 
rat donors, and gave them to the rats with MG. The recipient rats achieved suppression of MG 
from the transfer Tregs. When the researchers took Tregs from the sick rats, cultured them, and 
transferred them back, MG was not suppressed (Aricha et al. 2016). This was because the Tregs, 
though normal in number, had functional impairments and could not suppress immune activity. 
They tried this step again, but improved the function of the rat’s Tregs by stimulating them with 
dendritic cells to improve function. When the functionally improved Tregs were administered 
back into the rats, MG was successfully suppressed. (Aricha et al. 2016). 
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Type 1 diabetes is currently one of the most studied autoimmune diseases for the therapy 
of adoptive transfer using Tregs. Early clinical trials, as the one described above, have had hopeful 
and beneficial results. The next step is to increase the number of trials and increase the number 
of patients in each trial. Many trials are currently underway and we will have to wait for results. 
For other autoimmune disorders, like MG, trials are still being done on animal models, but as 
successful experiments show positive results, human trials will begin. Early clinical trials on 
other autoimmune diseases are currently begin done or are in the process of recruiting patients. 
Again, we will have to wait for the results of these trials to see if what we learn from animal 
models can be transferred over to humans. It is imperative that researchers share results with one 
another, so data on timing of transfer, method of transfer, characteristics of patients, and other 
factors can be looked at and concise conclusions can be made about the effectiveness of adoptive 
transfer of Tregs. 
 
Allergic Disorders 
When looking at allergic disorders, adoptive transfer therapy has only been tested in mice 
so far, but with promising results. It has been shown that mice with food allergies can overcome 
them by receiving transferred Tregs from non-allergic mice (Yamashita et al. 2011). The mice no 
longer showed any signs of allergic reaction when exposed to the allergen. In another study, 
normal T cells were taken from mice with asthma and then converted to iTregs in culture. When 
reintroduced into the mice, the iTregs were capable of controlling airway inflammation (Agua-
Doce and Graca 2012). These researchers used the cytokine TGF-β to convert the T cells into 
functional iTregs. IL-10 and IL-2 are also known cytokines that drive the development of Tregs. 
The environment of a T cell is important because what the T cell is exposed to will dictate what 
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it develops into. Mice deficient in IL-10 show signs of airway inflammation (Agua-Doce and 
Graca 2012). This may be because the environment, lacking IL-10, is not favorable for Treg 
development. Tregs secrete both IL-10 and TGF-β, so the presence of them will induce more to be 
converted.  
Aside from the few mice studies looking into food allergy and asthma, there are not many 
other studies that have been conducted. A reason for this may be that for most people, allergies 
are burdensome, but do not affect quality of life that greatly. While other health issues, such as 
autoimmune disorders or transplant rejection, significantly affect the health of the individual. 
These diseases have taken front stage in researching adoptive transfer of Tregs because those 
affected would have the greatest benefit. Another possible reason is that the process of adoptive 
transfer is laborious and costly, so the focus is on the more taxing diseases. In the future, if more 
data comes out showing the significant benefit of Tregs, the therapy may open up to allergic 
diseases, especially for those individuals who are greatly affected.  
 
Transplants 
 When an individual requires a transplant, it is important that they receive an organ that is 
a “match”. With blood, a recipient must receive blood from a person whose blood type is 
compatible with theirs. For an organ, this process is similar, but more complicated.  Not only 
must blood type match, but human leukocyte antigen (HLA) must also be matched. HLA is a 
type of antigen on cells that allow for the body to recognize these cells as belonging to itself, 
thus they will not be attacked by the immune system. There are one hundred different antigens, 
but of these, six are the most important when matching organs (UC Davis Transplant Center 
2016). Except in the case of twins, it is rare for two people to have the same identical six. 
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Doctors try and match as many HLAs as possible to ensure a match. Without matching, the 
immune system of the recipient patient would recognize the donor organ as foreign and attack it, 
leading to organ rejection. Still, even with matching, there still is a chance that organs may be 
rejected by the patient (UC Davis Transplant Center 2016). For this reason, patients receive 
antirejection medication to prevent rejection from occurring. However, long term satisfaction is 
still low, as patients can be on medication for the rest of their lives and can suffer complications 
due to long term immune suppression (Todo et al. 2016). These complications include infection, 
malignancies, kidney disorders from the toxicity of the medication, and still the chance of 
rejection. Tregs with their immune suppression capabilities are being looked at as a potential new 
therapy to prevent rejection. 
 Dr. Todo and colleagues from the Research Institute of St. Mary’s Hospital in Japan, 
studied the effect of adoptive transfer of Treg cells on ten patients who received a liver transplant. 
At the end of the study, all ten patient were maintaining good transplant function and none of 
these patients had any adverse effects of treatment (Todo et al. 2016). Seven of these patients no 
longer needed immunosuppressive (IS) drugs. IS drugs were discontinued within eighteen 
months of the transplant and the patients were drug free until the end of the study. Some patients 
have been drug free for twelve months, while others have been drug free for thirty-three months 
at the end of the study. These patients are considered to have achieved operational tolerance 
(OT), which means to have maintained transplant function without the need of IS drugs (Todo et 
al. 2016). This is considered a rare event. The other three patients, who originally had an 
autoimmune disorder affecting the liver, developed mild rejection after cessation of IS drugs and 
needed to be placed back on them.  
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 The researchers concluded a few significant results. One is that the process they used to 
extract, develop, and test Tregs was practical and less expensive than other methods (Todo et al. 
2016). The amount the researchers used is lower than other reported values in previous studies. 
Secondly, this study, published in 2016, is the first to report OT achievement using Treg therapy. 
They demonstrated that patients could be weaned off of IS drugs as soon as six months after 
transplantation occurred and completely terminate the use of IS drugs by eighteen months (Todo 
et al. 2016). OT rates of patients in this study were higher than that of patients who received only 
traditional IS drugs (Todo et al. 2016). Of the three patients that developed mild rejection, Dr. 
Todo had originally believed that the transfer of Tregs would aid the patients with autoimmune 
disorders, but this was not the case. As to why this happened, Dr. Todo theorized that it has 
something to do with the genetics of the patients, but this was not looked into as it was not 
included in the realm of the study (Todo et al. 2016).  
 Several limitations of this study exist. First, to achieve statistically significant results, Dr. 
Todo needed at least forty patients to participate, but was only able to get ten patients in the time 
frame of the study (Todo et al. 2016). Secondly, patients had received transplants from living 
donors, rather than deceased donors. Living donors typically have a higher HLA match then 
deceased ones, thus the chance of achieving OT is possibly higher among these patients (Todo et 
al. 2016). Another limitation was the limited follow up period. Long term follow up, five years 
or even ten years after transplantation, was not possible so we cannot be sure of the long term 
outcome of these patients. Still, this study displays the potential that Treg therapies have on the 
success of transplants. As a result, further study is being conducted on a large sample size with a 
longer follow up period (Todo et al. 2016).  
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Other Therapies using Tregs 
 Other types of treatment using Tregs other than adoptive transfer is possible. One therapy 
is to treat patients with low dosages of IL-2. In patients who have a normal population of Tregs, 
but the cells show diminished function, exposing them to IL-2 can improve their function. This is 
a possible therapy for autoimmune and allergic disorders, as well as transplant patients. A study 
out of Harvard Medical School looked at this type of therapy used in corneal transplants on mice. 
The cornea is a transparent part of the eye that covers the pupil. Transplant survival is low in 
patients whose eye shows signs of chronic inflammation, chronic infection, or have received 
trauma (Tahvildari et al. 2016). This is because there is already prior inflammation at the site of 
the transplant. Even with IS treatment, long term survival of the transplanted cornea is not 
guaranteed and complications can arise. Similar to adoptive transfer in liver transplants, 
promoting Treg function with IL-2 will hopefully increase good outcomes of transplants.  
 The mice in this study received low doses of IL-2 starting three days before 
transplantation in order to begin boosting Treg function. During the first week, dosage was 
continued as this is the peak time for rejection (Tahvildari et al. 2016). From week two to week 
six, IL-2 was given twice a week, by this time, most corneal transplants are rejected (Tahvildari 
et al. 2016). At the end of the study, the mice showed significantly improved rates of transplant 
survival. This was also the first study that used IL-2 alone, with no other IS drugs (Tahvildari et 
al. 2016). Enhancing Treg numbers and their function was enough to overcome the prior 
inflammation at the site of the transplant. Low dose IL-2 has also been used on autoimmune 
disorders such as T1D and has improved disease prognosis as well.  
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Obstacles in Therapy with Tregs 
 Many obstacles exist in Treg therapy which can impair results. One problem is that there 
is no clear way of identifying all Tregs. We know that most Tregs can be identified by the FOXP3 
transcription factor, but not all Tregs have this marker. Without a clear marker, it can be difficult 
to isolate a population of Tregs from a patient (Trzonkowski et al. 2015). When isolating Tregs, 
there is not just one method of doing so, but many. Different experiments use different methods, 
which can make it difficult to come to a conclusion on which method is the best one. Another 
conclusion that needs to be made is which method is the most practical for researchers to use. 
Ways to create a functional Treg population are also disputed. Both IL-10, IL-2, and TFG-β can 
stimulate a functional Treg population. There is also debate on whether low doses or high doses of 
these cytokines is the right exposure (Tahvildari et al. 2016; Trzonkowski et al. 2015). Creating a 
substantial population size can also be difficult. Some patients already have a diminished Treg 
population so getting enough viable cells from them can difficult. Also previously mentioned is 
that smaller individuals, such as children, cannot give enough blood for researchers to obtain a 
substantial amount. Consequently, the samples have to be cultured even more, possibly beyond 
what current equipment can do (Trzonkowski et al. 2015). 
 Regulations placed on facilities and trials can severely limit what researchers are trying to 
accomplish. While these are meant to benefit patients for their safety, it hinders researchers. 
Adoptive transfer is considered a cell-based therapy and thus has harsher restrictions than 
pharmaceuticals (Trzonkowski et al. 2015). For academic institutions and small companies with 
limited resources, it can be a great challenge for them to comply with regulations. It is possible 
for certain cell-based therapies to be given orphan drug status. Orphan drug status is given to 
drugs that are designed to treat a specific rare disease. The profit of these drugs is far less than a 
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generic drug. By giving it orphan drug status some restrictions are lifted, making testing easier 
(Trzonkowski et al. 2015).  
 The clinical trials themselves possess a few problems. Researchers as of right now are not 
sure if Tregs work best at preventing the development of disease, or suppressing the disease after 
the development. Each case comes with its own set of obstacles. In terms of preventing, high risk 
patients must be identified. Genetics can help identify high risk patients. There is a vast array of 
autoimmune diseases, most with some genetic component. Family history can help identify those 
who might be genetically predisposed to certain disease. However, if no family history is 
available, genetic testing must be done. Genetic testing will only work if certain genes have been 
linked to disease, but for many disease, it is still unknown what genes can cause them. If therapy 
is given after the development of a particular disease, the question raised is when is the right 
timing? Is it most beneficial for treatment to begin right after diagnosis? Would patients who 
have had the disease for ten or twenty years benefit as well? All these questions means that 
extensive experimentation needs to be done. During the trials, it is also important that there is a 
long term follow up period. The reason why most of the time there isn't, is because grants and 
funding only last a few years. When funding stops, research stops. As a consequence, long term 
results are not thoroughly studied. Since Tregs suppress the immune system, there remains the 
possibility of increased risk of infection and the development of malignancies. These risk cannot 
be known unless there is long term follow up of patients.  
 Lastly, the cost of the therapy is currently very expensive. The cost of a single transfer 
can range anywhere from sixteen to forty thousand dollars (Trzonkowski et al. 2015). Most of 
this cost comes from the equipment needed to isolated and increase the Treg population. Some of 
this equipment can only be used once and the facilities they are located at can be expensive. On 
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top of that, personnel must be paid and the products need to be tested to ensure functional 
quality. If the process can be made less labor intensive over the upcoming years, the price should 
fall (Trzonkowski et al. 2015). There is also the risk that insurance companies may not cover this 
type of therapy. One main reason why is that, at the moment, Treg therapy has not been proven to 
be effective. To have insurance companies cover the cost, therapy needs to be proven to benefit a 
specific set of individuals.   
 
Conclusion  
 Over the years, researchers have learned more and more about the complexity of the 
immune system. Much of this started with Dr. Strachan suggesting that being born with older 
siblings would help protect against allergic disease. Since then, his idea called the hygiene 
hypothesis has grown and now includes autoimmune disease. The general belief is that less 
exposure to microbes causes the immune system to be underdeveloped. Whereas exposure to 
these microbes can actually train the immune system. This is also seen with parasitic worms. 
Countries with low incidence of worm infections have a higher incidence of allergic and 
autoimmune disorders. As technology has improved, researchers have been able to see why this 
is. The key player ends up being the T regulatory cell. Parasitic worms will promote a population 
of Tregs in order to increase their survival because the Tregs can suppress immune activity. Tregs 
were studied and it was shown that many individuals who have allergic or autoimmune disorders 
possess either a substantially lower population of Tregs or a population with compromised 
function. These general studies further cemented the role of microbes and parasitic worms in 
allergic and autoimmune diseases.  
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 With connections becoming too apparent to ignore, the big question of what to do with 
this information came about. One specific idea was the therapy of adoptive transfer, where Tregs 
would be taken from an individual, would be grown in culture, tested for appropriate function, 
and then transferred back into the patient. It is hoped that this new and improved population of 
Tregs would benefit the patient and alleviate the disease. Potential recipients would include those 
with autoimmune or allergic disorders, as well as transplant patients to reduce the risk of 
rejection. Early clinical trials have shown promising results. Patients with T1D have been able to 
get off insulin. Transplant patients have been able to stop using immunosuppressive drugs. 
Experiments using mice have shown that allergies can be alleviated and other autoimmune 
disorders can be treated as well. Future trials need to clearly assess any side effects of the 
treatment, including the possibility of increased risk of infection and malignancies.  Long term 
follow up needs to be planned as well to know how this therapy will work for patient many years 
out. It is imperative that institutions researching adoptive transfer share results with one another. 
This way, a clear conclusion on whether therapy works or not can be more easily made. 
Communication will also improve future trials and lower some barriers that adoptive transfer 
therapy has. Learning about the advantage of Tregs in therapy can advance the field of 
immunology and hopefully bring about alleviating the suffering of those burdened by allergic 
and autoimmune diseases.   
 
 
 
 
 
28 
 
References  
Matching and Compatibility [Internet]; c2016 [cited 2016 12/3]. Available from: 
http://www.ucdmc.ucdavis.edu/transplant/livingdonation/donor_compatible.html . 
Agua-Doce, A. and Graca L. 2012. Regulatory T cells and the control of allergic response. 
Journal of Allergy. 
Amoah, A., Boakye, D., van Ree, R., Yazdanbakhsh, M. 2014. Parasitic worms and allergies in 
childhood: Insights from population studies 2008-2013. Pediatric Allergy and Immunology 
25:208-217. 
Archia R., Reuvei D., Fuchs S., Souroujon M. 2016. Suppression of experimental autoimmune 
myasthenia gravis by autologous T regulatory cells. Journal of Autoimmunity 67:57-64. 
Braga, M., Schiavone, C., Di Gioacchino, G., De Angelis, I., Cavallucci, E., Lazzarin, F., 
Petrarca, C., Di Giocchino, M. 2012. Environment and T regulatory cells in allergy. Science 
of the Total Environment 423:193-201. 
Braza, F., Chesne, J., Castagnet, S., Magnan, A., Brouard, S. 2014. Regulatory function of B 
cells in allergic diseases. Allergy 69:1454-1463. 
Correale, J. and Farez, M. 2011. Journal of Neuroimmunology 233: 6-11.  
Creusot, R.J., Battaglia, M., Roncarolo, M., Fathman, G. 2016. Concise review: Cell-based 
therapies and other non-traditional approaches for type 1 diabetes. Stem Cells 34:809-819. 
Eiwegger, T., Gruber, S., Szepfalusi, Z., Akdis, C. 2012. Novel developments in the mechanisms 
of immune tolerance to allergens. Human Vaccines and Immunotherapeutics 8(10):1485-
1491.  
ElEssaway, B. and Li, X. 2015. Type 1 diabetes and T regulatory cells. Pharmacological 
Research 98:22-30. 
Gazzinell, R., Wysocka, M., Hieny, S., Scharton-Kersten, T., Cheever, A., Khun, R., Muller, W., 
Trinchieri, G., Sher, A. 1996. In the absence of endogenous IL-10, mice acutely infected 
with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells 
and accompanied by overproduction of IL-2, IFN-gamma and TNF-alpha. Journal of 
Immunology 157:798-805.   
Gershon, R. and Kondo, K. 1971. Infectious immunological tolerance. Immunology 21:903-914. 
Gitelman, S. and Bluestone, J. 2016. Regulatory T cell therapy for type 1 diabetes: May the force 
be with you. Journal of Autoimmunity 71:78-87. 
29 
 
Holbreich, M., Genuneit, J., Weber, J., Braun-Fahrlander, C., Waser, M., von Mutius, E. 2012. 
Amish children living in northern indiana have a very low prevalence of allergic 
sensitization. Journal of Allergy and Clinical Immunology 129(6):1671-1973. 
Karlsson, M., Rugtveit, J., Brandtzaeg, P. 2004. Allergen-responsive CD4+ CD25+ regulatory T 
cells in children who have outgrown cow’s milk allergy. Journal of Experimental Medicine 
199:1679-1688. 
Kondrashova, A., Seiskari, T., Ilonen, J., Knip, M., Hyoty, H. 2013. The “Hygiene hypothesis” 
and the sharp gradient in the incidence of autoimmune and allergic diseases between 
Russian Karelia and Finland. APMIS 121:478-93. 
Kuhn, C., Besancon A., Lemoine S., You S., Marquet C., Candon S., Chatenoud L. 2016. 
Regulatory mechanism of immune tolerance in type 1 diabetes and their failures. Journal of 
Autoimmunity71:69-77.  
Maizels, R.M. 2016. Parasitic helminth infections and the control of human allergic and 
autoimmune disorders. Clinical Microbiology and Infection 22:481-486. 
Ng, T.H.S, Britton, G., Hill, E., Verhagen, J., Burton, B., Wraith, D. 2103. Regulation of 
adaptive immunity; the role of interleukin-10. Frontiers in Immunology 4(129). 
Okada, H., Kuhn, C., Feiller, H., Bach, J. 2010. The 'hygiene hypothesis' for autoimmune and 
allergic diseases: An update. Clinical and Experimental Immunology 160:1-9. 
Perakakis, N. and Mantzoros, C. 2016. Immune therapy in type 1 diabetes mellitus - attempts to 
untie the Gordian knot? Metabolism 65:1278-1285. 
Platts-Mills, T. 2015. The allergy epidemics: 1870-2010. Journal of Allergy and Clinical 
Immunology. 
 Rahman, M. 2016. Immunoglobulins [Internet]; c2016 [cited 2016 12/3]. Available from: 
https://www.bio-rad-antibodies.com/immunoglobulins-classes-subclasses.html. 
Smits, H. 2012. B cells in allergic diseases: Bad or better? Autoimmunity 45(5):415-426. 
Stranford S., Owen J., Punt J. 2013. Kuby Immunology. 7th. New York.  
Summers, R., Elliott D., Urban, J., Thompson, R., Weinstock, J. 2005. Trichuris suis therapy in 
Chron’s disease. Gut 54:87-90.   
Symmons, D. 1995. Frequency of lupus in people of African origin. Lupus 4:176-178. 
Tahvildari, M., Omoto, M., Chen, Y., Emami-Naeini, P., Inomata, T., Dohlman, T., Kaye, A., 
Chauhan, S., Dana, R. 2016. In vivo expansion of regulatory T cells by low-dose interleukin 
30 
 
treatment increases allograft survival in corneal transplants. Transplantation 100(3):525-
532. 
Tang, Q. and Lee, K. 2012. Regulatory T-cell therapy for transplantation: how many cells do we 
need? Organ Transplantation 17(4):349-354.  
Todo, S., Yamashita, K., Goto, R., Zaitsu, M., Nagatsu, A., Oura, T., Watanabe, M., Aoyagi, T., 
Suzuki, T., Shimamura, T. 2016. A pilot study of operational tolerance with a regulatory T-
cell-based cell therapy in living donor live transplants. Hepatology 00. 
Trinchieri, G. 2007. Interleukin-10 production by effector T cells: Th1 cells show self control. 
Journal of Experimental Medicine 204(2):239-243.  
Trzonkowski, P., Bieniaszewska, M., Ju’sci I nska, J. 2009. First-in-man clinical results of the 
treatment of patients with graft versus host disease with human ex vivo expanded CD4+ 
CD25+ CD127- T regulatory cells. Clinical Immunology 133:22-26. 
Trzonkowski, P., Bacchetta, R., Battaglia, M., Berglund, D., Bohnenkamp, H., ten Brinke, A., 
Bushell, A., Cools, N., Geissler, E., Gregori, S., van Ham, S., Hilkens, C., Hutchinson, J., 
Lombardi, G., Madrigal, J., Marek-Trzonkowska, N., Martinez-Caceres, E., Roncarolo, M., 
Sanchez-Ramon, S., Saudemont, A., Sawitzki, B. 2015. Hurdles in therapy with regulatory 
T cells. Immunology 304(7).  
Versini, M., Jeandel, P., Bashi, T., Bizzaro, G., Blank, M., Shoenfeld, Y. 2015. Unraveling the 
hygiene hypothesis of helminthes and autoimmunity: Origins, pathophysiology, and clinical 
applications. BMC Medicine 13(81). 
Weinersmith, K. and Earley, R. 2016. Better with your parasites? lessons for behavior ecology 
from evolved dependence and conditionally helpful parasites. Animal Behavior 118:123-
133. 
Wen, L, Ley, R., Volchkov, P., Stranges, P., Avanesyan, L., Stonebraker A. 2008. Innate 
immunity and intestinal microbiota in the development of type 1 diabetes. Nature 455:1109-
1113.  
Yamashita, H., Takahashi, K., Tanaka, H., Nagai, H., Inagaki, N. 2012. Overcoming food allergy 
through acquired tolerance conferred by transfer of tregs in a murine model. Allergy 67:201-
209. 
 
 
 
